التفاصيل البيبلوغرافية
| العنوان: |
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study. |
| المؤلفون: |
Padilla-Galo, Alicia, Moya Carmona, Isabel, Ausín, Pilar, Carazo Fernández, Luis, García-Moguel, Ismael, Velasco-Garrido, José Luis, Andújar-Espinosa, Rubén, Casas-Maldonado, Francisco, Martínez-Moragón, Eva, Martínez Rivera, Carlos, Vera Solsona, Elisabet, Sánchez-Toril López, Fernando, Trisán Alonso, Andrea, Blanco Aparicio, Marina, Valverde-Monge, Marcela, Valencia Azcona, Borja, Palop Cervera, Marta, Nuevo, Javier, Sánchez Tena, Jesús, Resler, Gustavo |
| المصدر: |
Respiratory Research; 10/5/2023, Vol. 24 Issue 1, p1-14, 14p |
| مصطلحات موضوعية: |
ASTHMATICS, NASAL polyps, TREATMENT effectiveness, DISEASE remission, STANDARD deviations, EOSINOPHILS |
| مصطلحات جغرافية: |
SPAIN |
| مستخلص: |
Background: The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods: ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables. Results: A total of 204 SEA patients were evaluated. Mean (standard deviation, SD) age of the study population was 56.4 (12.4) years, 62.3% were women and mean (SD) duration of asthma was 15.1 (12.7) years. Median (Q1–Q3) follow-up duration was 19.5 (14.2–24.2) months. At baseline, 72.6% of the overall population (OP) presented blood eosinophil counts ≥ 300 cells/µL; 36.8% had comorbid chronic rhinosinusitis with nasal polyps (CRSwNP); 84.8% reported at least one severe exacerbation, and 29.1% were OCS-dependent. At 1 year of follow-up, patients receiving benralizumab treatment had a 85.6% mean reduction in exacerbations from baseline, and 81.4% of patients achieved zero exacerbations. We also found a clinically relevant mean (SD) increase in pre-bronchodilator (BD) FEV1 of 331 (413) mL, with 66.7% of patients achieving a pre-BD FEV1 increase ≥ 100 mL, and 46.3% of patients achieving a pre-BD FEV1 ≥ 80% of predicted. Regarding symptom control, 73.8% of the OP obtained an ACT score ≥ 20 points. After 1 year of follow-up, mean reduction in the daily OCS dose was 70.5%, and complete OCS withdrawal was achieved by 52.8% of the OCS-dependent patients. Almost half (43.7%) of the OP on benralizumab met all four criteria for clinical remission. Patients with concomitant CRSwNP obtained similar or enhanced outcomes. Conclusions: These data support the real-world benefits of benralizumab in SEA patients, and particularly in those with concomitant CRSwNP. Trial registration: NCT04648839. [ABSTRACT FROM AUTHOR] |
|
Copyright of Respiratory Research is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder